Monday, 2 November 09:00 – 12:00

SC2: Mutation and Selection Strategies for Multi-Parameter Antibody Optimization

Co: Instructors:
William Finlay, Ph.D., Senior Director, Global Biotherapeutic Technologies, Pfizer, Inc.

Orla Cunningham, Ph.D., Associate Director, Global Biotherapeutic Technologies, Pfizer, Inc.

In therapeutic antibody discovery, few lead molecules meet all of the demanding standards required to become a drug. As a result, most antibodies will require some form of engineering and optimisation. This course aims to help attendees navigate the complex workflows and technological options required to be successful.

• Gain a thorough introduction to the antibody engineering field; examine antibody properties and discover optimal engineering techniques
• Select the most effective methods of antibody discovery, humanisation and optimisation for your antibody research projects
• Implement different strategies to ensure optimal antibody developability, including early stage screening and molecular assessment
• Enhance your affinity improvement research by discussing tailored selection and screening strategies, and become familiar with alternative antibody library designs for affinity optimisation